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background
 
Faced with unsatisfactory results of treatment for advanced Hodgkin’s disease, we in-
vestigated three combinations of chemotherapy.
 
methods
 
From 1993 to 1998, 1201 eligible patients 15 to 65 years of age who had newly diag-
nosed Hodgkin’s disease in unfavorable stage IIB or IIIA or stage IIIB or IV were ran-
domly assigned to receive eight cycles of cyclophosphamide, vincristine, procarbazine,
and prednisone alternating with doxorubicin, bleomycin, vinblastine, and dacarbazine
(COPP-ABVD); bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, pro-
carbazine, and prednisone (BEACOPP); or increased-dose BEACOPP, each followed by
local radiotherapy when indicated. Enrollment in the COPP-ABVD group was stopped
in 1996 owing to inferior results.
 
results
 
For the final analysis, 1195 of 1201 patients could be evaluated: 260 in the COPP-ABVD
group, 469 in the BEACOPP group, and 466 in the increased-dose BEACOPP group; the
median follow-up was 72, 54, and 51 months, respectively. The rate of freedom from
treatment failure at five years was 69 percent in the COPP-ABVD group, 76 percent in
the BEACOPP group, and 87 percent in the increased-dose BEACOPP group (P=0.04 for
the comparison of the COPP-ABVD group with the BEACOPP group and P<0.001 for the
comparison of the increased-dose BEACOPP group with the COPP-ABVD group and
with the BEACOPP group), and the five-year rates of overall survival were 83 percent, 88
percent, and 91 percent, respectively (P=0.16 for the comparison of the COPP-ABVD
group with the BEACOPP group, P=0.06 for the comparison of the BEACOPP group
with the increased-dose BEACOPP group, and P=0.002 for the comparison of the
COPP-ABVD group with the increased-dose BEACOPP group). Rates of early progres-
sion were significantly lower with increased-dose BEACOPP than with COPP-ABVD or
standard BEACOPP. 
 
conclusions
 
Increased-dose BEACOPP resulted in better tumor control and overall survival than did
COPP-ABVD.
abstract
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he standard chemotherapy com-
 
binations for advanced Hodgkin’s disease
are mechlorethamine, vincristine, procar-
bazine, and prednisone (MOPP) and doxorubicin,
bleomycin, vinblastine, and dacarbazine (ABVD),
 
1-5
 
yet 30 to 40 percent of cases progress or relapse
and respond poorly to salvage treatment.
 
6,7
 
 In 1990
the German Hodgkin’s Lymphoma Study Group
planned a sequence of clinical trials on the basis
of results of experiments in animals, retrospective
analyses of clinical data, and mathematical mod-
els
 
8,9
 
 suggesting that more rapid administration
could improve the disease-free survival rate by 3 per-
cent and that a moderate dose escalation could im-
prove this rate by an additional 10 percent.
 
10,11
 
 Our
trial compared three regimens: COPP-ABVD (with
cyclophosphamide instead of mechlorethamine); a
combination of bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procarbazine, and
prednisone (BEACOPP) in standard doses; and
BEACOPP in increased doses.
Pilot and dose-finding studies confirmed the fea-
sibility of BEACOPP and of the escalation of the dos-
es of cyclophosphamide, etoposide, and doxorubi-
cin to 192, 200, and 140 percent of the standard
doses, respectively.
 
12,13
 
 The phase 3 trial aimed to
assess the efficacy and toxicity of standard and in-
creased-dose BEACOPP. Interim analyses have dem-
onstrated the effectiveness of BEACOPP.
 
14,15
 
 We
present the results of the final data analysis as of
August 2001.
 
patients
 
Eligible patients were 15 to 65 years old with newly
diagnosed, untreated Hodgkin’s disease in Ann Ar-
bor clinical stage IIB or IIIA with a large mediastinal
mass (more than one third of the maximal thoracic
diameter) alone or in combination with extranodal
lesions or massive splenic involvement (with diffuse
infiltration or more than five focal lesions, as deter-
mined by computed tomography and sonography)
or both; stage IIIA with an elevated erythrocyte sed-
imentation rate (more than 50 mm per hour in
asymptomatic patients and more than 30 mm per
hour in patients with B symptoms) or three or more
involved nodal areas, or both; or Stage IIIB or IV.
Patients had to have a Karnofsky index above 70 per-
cent, to be negative for the human immunodeficien-
cy virus, to be free of concurrent disease that might
hinder treatment, and to give written informed con-
sent. Patients were registered and treated in 219
hospitals and practices in Germany, Switzerland,
Austria, and the Czech Republic (listed in the Ap-
pendix). Review of biopsy specimens by a panel of
lymphoma pathologists was an obligatory part of
the protocol.
 
study design
 
After clinical staging had been conducted accord-
ing to previously reported methods,
 
14
 
 patients were
randomly assigned (in a centralized, open fashion
by telephone and by computer) to one of three
chemotherapy regimens: eight cycles of COPP al-
ternating with ABVD; eight cycles of standard-
dose BEACOPP; or eight cycles of increased-dose
BEACOPP, with the administration of filgrastim
from day 8 of each cycle until the leukocyte count
returned to normal (Table 1). Randomization was
stratified (i.e., balance among the groups was main-
tained) according to the participating center, tumor
stage (IIB or IIIA vs. IIIB or IV), and the presence or
absence of a large mediastinal mass.
For the increased-dose BEACOPP group, the
dose could be reduced in subsequent cycles if pre-
t
methods
 
* The days were counted from the beginning of the double cycle of COPP-ABVD. 
The regimen was repeated on day 57.
† The regimen was repeated on day 22.
 
‡ The absolute dose of vincristine was limited to 2.0 mg.
 
Table 1. Planned Regimens of Cyclophosphamide, Vincristine, Procarbazine, 
Prednisone, Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine 
(COPP-ABVD) and Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, 
Vincristine, Procarbazine, and Prednisone (BEACOPP).
Drug COPP-ABVD
Standard
BEACOPP
Increased-Dose
BEACOPP
 
Single
Dose
Days
Given*
Single
Dose
Days
Given†
Single
Dose
Days
Given†
 
mg/m
 
2
 
mg/m
 
2
 
mg/m
 
2
 
Bleomycin 10 29, 43 10 8 10 8
Etoposide — — 100 1–3 200 1–3
Doxorubicin 25 29, 43 25 1 35 1
Cyclophosphamide 650 1, 8 650 1 1200 1
Vincristine 1.4‡ 1, 8 1.4‡ 8 1.4‡ 8
Procarbazine 100 1–14 100 1–7 100 1–7
Prednisone 40 1–14 40 1–14 40 1–14
Vinblastine 6 29, 43 — — — —
Dacarbazine 375 29, 43 — — — —
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defined toxic effects — World Health Organization
(WHO) grade 4 (life-threatening) leukopenia for
more than four days; WHO grade 4 thrombocyto-
penia, infection, or mucositis; or an adverse effect
that required a two-week delay in treatment —
occurred in a given cycle.
 
13
 
 After each such event,
the doses of cyclophosphamide and etoposide were
reduced by one level on a five-level scale ranging
from standard to escalated doses; if toxic effects
occurred in two successive cycles, standard doses
were used for all subsequent cycles. The tumor stage
was reevaluated after four and eight cycles by means
of a clinical examination and imaging or biopsy
methods appropriate to the site of initial involve-
ment (computed tomography, sonography, bone
scintigraphy, bone marrow biopsy, or liver biopsy).
After the completion of chemotherapy, sites of ini-
tial bulky disease (those at least 5 cm in diameter)
received 30 Gy of irradiation and any residual tumor
received 40 Gy. Inactive sites that were apparently
treatment-related artifacts were considered to be
part of a complete remission and were not irradiat-
ed. The outcome of treatment was assessed three
months after the completion of the protocol.
 
statistical analysis
 
The primary end point of the trial was freedom from
treatment failure, with progression during treat-
ment, lack of complete remission at the end of pro-
tocol treatment, relapse, and death from any cause
counted as adverse events. The rate of overall sur-
vival and the outcome of treatment (complete re-
mission or early progression) were secondary end
points. The rates of freedom from treatment failure
and overall survival were compared between groups
with use of the Kaplan–Meier method and the log-
rank test, whereas outcomes were compared with
use of the chi-square test (all methods were pre-
specified).
The trial was designed to test the hypotheses
 
Figure 1. Treatment Assignments and Numbers of Patients Included in the Analysis.
 
After randomization, 81 patients were found to be ineligible and were excluded, because the pathological-review panel 
decided that the patient did not have Hodgkin’s disease, the patient met clinical exclusion criteria that were known but 
not considered at the time of randomization, or the patient had not given consent. Patients were included in the analysis 
according to the intention-to-treat principle. Six patients were excluded because they had insufficient follow-up informa-
tion to determine the treatment outcome. Patients were deemed to have received the full course of allocated chemother-
apy if the dose received was at least 85 percent of the intended, unreduced dose, averaged over all drugs, and to have 
received a partial course if they had received 15 to 85 percent of the intended, unreduced dose. COPP-ABVD denotes cy-
clophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, and dacarbazine, and 
BEACOPP bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone.
1282 Patients recruited
288 Assigned to COPP-ABVD
25 Excluded
12 Did not have Hodgkin’s 
disease
13 Met clinical exclusion criteria
263 Eligible
3 Lost to follow-up
260 Included in the analysis
253 Received full course
6 Received partial course
1 Received no study drug
28 Excluded
19 Did not have Hodgkin’s 
disease
9 Met clinical exclusion criteria
470 Eligible
1 Lost to follow-up
469 Included in the analysis
459 Received full course
7 Received partial course
3 Received no study drug
498 Assigned to standard
BEACOPP
28 Excluded
15 Did not have Hodgkin’s 
disease
12 Met clinical exclusion criteria
1 Declined to give consent
468 Eligible
2 Lost to follow-up
466 Included in the analysis
421 Received full course
41 Received partial course
4 Received no study drug
496 Assigned to increased-dose
BEACOPP
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that BEACOPP (irrespective of the dose) results in a
higher rate of freedom from treatment failure than
COPP-ABVD and that increased-dose BEACOPP re-
sults in a higher rate of freedom from treatment fail-
ure than standard BEACOPP. For the study to have a
statistical power of 80 percent to detect an absolute
difference of 9 to 10 percent in either of these com-
parisons, we determined that 900 patients would
have to be enrolled. All analyses were conducted ac-
cording to the intention-to-treat principle, with the
proviso that patients for whom an exclusion criteri-
on was discovered after randomization, on the basis
of a clinical examination or examination of biopsy
material obtained before randomization, would be
excluded as ineligible.
The study design called for interim analyses af-
ter 2, 3, 4, and 5 years and a final analysis after 7
 
1
 
⁄
 
2
 
years. We used a truncated sequential probability
ratio strategy as proposed by Whitehead (nominal
alpha of 0.1, with 80 percent power to detect a haz-
ard ratio of 0.7 for both BEACOPP groups together
as compared with the COPP-ABVD group) to deter-
mine whether the trial should be stopped early.
 
16
 
 All
tests were two-sided, and P values were not adjust-
ed for sequential analysis.
Recruitment began in February 1993 and ended in
March 1998. Random assignment to the increased-
dose BEACOPP group began after the completion
of the dose-finding study in 1994; subsequently,
unequal randomization probabilities were used to
equalize the numbers in each group. At the first in-
terim analysis in September 1996, the early stopping
boundary was crossed, with the demonstration that
both BEACOPP groups together were significantly
superior to COPP-ABVD in terms of the rate of free-
dom from treatment failure (P=0.03, adjusted for
Whitehead sequential analysis).
 
14
 
 Therefore, as-
signment to the COPP-ABVD group was stopped.
Assignments to the other two groups were increased
so that each group would include 500 patients,
thus permitting a more precise comparison of the
groups. We then used a group sequential design ac-
cording to the method of Peto to determine wheth-
er early-stopping criteria were met in the BEACOPP
groups.
The final analysis was completed in August 2001.
Of the 1282 patients we enrolled, 81 were subse-
quently found to be ineligible, because of the wrong
diagnosis in 46, concurrent disease in 8, incorrect
staging in 10, other clinical exclusion criteria in 16,
and lack of informed consent from 1 (Fig. 1). All but
6 of the 1201 eligible patients had sufficient data to
determine the outcome of treatment. There were
260 patients in the COPP-ABVD group (assignment
to this group was stopped early), 469 in the standard
BEACOPP group, and 466 in the increased-dose
BEACOPP group. The characteristics of the patients
were balanced among the three groups (Table 2).
The incidence of acute hematologic effects was
similar in the COPP-ABVD and standard BEACOPP
groups but was greatly increased in the increased-
dose BEACOPP group (Table 3). In this group, grade
3 and 4 leukopenia was common in all eight cycles,
results
 
* Because of rounding, percentages may not total 100. COPP-ABVD denotes cy-
clophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomy-
cin, vinblastine, and dacarbazine; BEACOPP bleomycin, etoposide, doxorubi-
cin, cyclophosphamide, vincristine, procarbazine, and prednisone; and 
LRCHD lymphocyte-rich classic Hodgkin’s disease.
† Data were available for 76 percent of patients: 72 percent of patients in the 
COPP-ABVD group, 76 percent in the standard BEACOPP group, and 77 per-
cent in the increased-dose BEACOPP group.
‡ Bulky disease was defined as a mass that was at least 5 cm in diameter.
§ The international prognostic index was calculated according to the method of 
Hasenclever and Diehl.
 
17
 
 A score of 0 indicates the absence of all adverse 
prognostic factors, and a score of 7 the presence of all adverse prognostic fac-
 
tors. Data were available for 79 percent of patients in each group.
 
Table 2. Characteristics of the Patients.*
Characteristic
COPP-
ABVD
(N=260)
Standard
BEACOPP
(N=469)
Increased-Dose
BEACOPP 
(N=466)
 
Age
50–65 yr (%)
Median (yr)
16
32.1
18
32.7
15
31.5
Male sex (%) 57 63 62
Histologic review (%)†
Lymphocyte predominant/LRCHD
Nodular sclerosis
Mixed cellularity
Lymphocyte depletion
Unclassified or diagnosis of 
Hodgkin’s disease uncertain
6
61
23
2
8
4
64
20
3
9
4
69
18
2
8
Clinical or pathological stage (%)
IIB
IIIA
IIIB
IVA
IVB
Laparotomy performed
9
31
29
9
23
9
14
24
28
9
26
6
16
21
31
10
23
5
Bulky disease (%)‡ 58 68 67
International prognostic index (%)§
0–1
2–3
4–7
28
38
13
22
41
16
28
38
13
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whereas the frequency of thrombocytopenia and
anemia increased during the last four cycles. Grade
3 or 4 infections occurred in 16 percent of patients
in the standard BEACOPP group and 22 percent
of those in the increased-dose BEACOPP group.
The incidence of fatal acute treatment-related ef-
fects was similar (less than 2 percent) among the
groups. A detailed report of the acute hematologic
effects and administered doses has been published
previously.
 
18
 
Between 73 percent and 99 percent of patients
received at least 80 percent of the planned total dose.
In the increased-dose BEACOPP group, the doses of
cyclophosphamide gradually decreased, from 192
percent of the planned standard dose in the first cy-
cle to 148 percent of this dose in the eighth cycle;
similar trends were observed for etoposide (from
198 percent initially to 152 percent) and doxorubicin
(from 139 percent initially to 126 percent). The me-
dian duration of chemotherapy from the first to the
last day of drug administration was 46.3 weeks in
the COPP-ABVD group (planned, 30 weeks), 24.4
weeks in the BEACOPP group (planned, 23 weeks),
and 24.7 weeks in the increased-dose BEACOPP
group (planned, 23 weeks). The percentage of pa-
tients who received radiotherapy was 64 percent in
the COPP-ABVD group and 71 percent in the other
two groups.
Progression occurred in 27 of 260 patients in
the COPP-ABVD group (10 percent) during or up
to three months after treatment, 36 of 469 in the
BEACOPP group (8 percent), and 9 of 466 in the
increased-dose BEACOPP group (2 percent); the dif-
ference between the two BEACOPP groups was sig-
nificant (P<0.001), as was that between increased-
dose BEACOPP and COPP-ABVD (P<0.001). The
rate of complete remission was higher in the the two
BEACOPP groups than in the COPP-ABVD group
(Table 4). The median follow-up was 72 months in
the COPP-ABVD group, 54 months in the standard
BEACOPP group, and 51 months in the increased-
dose BEACOPP group (follow-up was longer in
the COPP-ABVD group because enrollment was
stopped early). The rate of freedom from treatment
failure was significantly higher at five years in the
standard BEACOPP group than in the COPP-ABVD
group (76 percent [95 percent confidence interval,
72 to 80 percent] vs. 69 percent [95 percent confi-
dence interval, 63 to 75 percent], P=0.04) and was
highest in the increased-dose BEACOPP group (87
percent [95 percent confidence interval, 83 to 91
percent], P<0.001 for the comparison with the
COPP-ABVD group and with the standard BEACOPP
group) (Fig. 2A and Table 4).
The deaths of 150 patients have been reported
to us: 49 in the COPP/ABVD group, 61 in the stand-
ard BEACOPP group, and 40 in the increased-dose
BEACOPP group. The overall survival rate (Fig. 2B
and Table 4) was higher in the standard BEACOPP
group than in the COPP-ABVD group at five years
(88 percent vs. 83 percent, P=0.16) and was high-
est in the increased-dose BEACOPP group (91 per-
cent, P=0.06 for the comparison with the standard
BEACOPP group and P=0.002 for the comparison
with the COPP-ABVD group). The causes of death
were recorded as Hodgkin’s disease in 68 patients,
complications of first-line treatment in 20, compli-
cations of salvage treatment in 14, a second neo-
plasm in 22, cardiorespiratory disease in 5, pulmo-
 
* The values are the percentages of patients with the given World Health Organ-
ization (WHO) grade adverse effect in one or more cycles. The frequencies of 
WHO grade 3 or 4 cardiac toxicity, medication-induced fever, renal or urinary 
effects, and allergies were all below 2 percent in each group. COPP-ABVD de-
notes cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, 
bleomycin, vinblastine, and dacarbazine, and BEACOPP bleomycin, etoposide, 
 
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone.
 
Table 3. Acute Adverse Effects of Chemotherapy.*
Adverse Effect
COPP-
ABVD
Standard
BEACOPP
Increased-Dose
BEACOPP
 
percent
 
Leukopenia
Grade 3
Grade 4
52
19
36
37
8
90
Thrombocytopenia
Grade 3
Grade 4
4
2
6
3
23
47
Anemia
Grade 3
Grade 4
4
1
16
1
51
15
Infection
Grade 3
Grade 4
2
1
13
3
14
8
Mucositis of grade 3 or 4 1 2 8
Respiratory tract effects of grade 3 or 4 2 5 4
Nausea of grade 3 or 4 20 12 20
Digestive tract effects of grade 3 or 4 3 2 4
Neurologic effects of grade 3 or 4 4 5 4
Skin effects of grade 3 or 4 1 1 3
Pain of grade 3 or 4 2 3 9
Hair loss of grade 3 or 4 36 75 79
The New England Journal of Medicine 
Downloaded from nejm.org at MAX DELBRUECK CENTRUM FOR MOLECULAR MED on April 2, 2014. For personal use only. No other uses without permission. 
 Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
348;24
 
www.nejm.org june 
 
12, 2003
 
beacopp for advanced hodgkin’s disease
 
2391
 
nary disease in 4, other causes in 9, and unknown
causes in 8. Fatal acute treatment-related adverse ef-
fects included sepsis in 11 patients (including 2 with
the acute respiratory distress syndrome), pneumo-
nia in 5, and thrombosis in 1; no details were avail-
able in the case of 3 patients.
To assess the efficacy of the three treatments ac-
cording to the prognosis, the patients were divided
into three subgroups on the basis of the internation-
al prognostic index.
 
17
 
 Owing to missing data, the
score was unavailable for 56 patients in the COPP-
ABVD group, 100 in the BEACOPP group, and 99 in
the increased-dose BEACOPP group (21 percent of
all patients). The rates of early progression, five-year
freedom from treatment failure, and overall survival
at five years for the three subgroups are shown in Ta-
ble 5. Within each of the three groups, the score for
the international prognostic index consistently cor-
related with the rates of early progression and five-
year freedom from treatment failure. Within each
prognostic subgroup, standard and increased-dose
BEACOPP resulted in lower rates of early progres-
sion and higher rates of freedom from treatment
failure and overall survival than did COPP-ABVD.
There was no indication of a statistical interaction
between the treatment group and the prognostic
group (P=0.91 for the interaction term in a Cox
regression model). Furthermore, all age groups
seemed to benefit from standard and increased-
dose BEACOPP, with the possible exception of those
who were 60 to 65 years of age (data not shown). In
this group of 64 patients, there were no significant
differences between the treatment groups (P=0.93).
Cases of secondary acute leukemia including
the myelodysplastic syndrome occurred in one pa-
tient in the COPP-ABVD group, four in the stand-
ard BEACOPP group, and nine in the increased-dose
BEACOPP group. The actuarial rate of secondary
acute leukemias five years after the diagnosis of
Hodgkin’s disease (according to a Kaplan–Meier
analysis) was 0.4 percent in the COPP-ABVD group,
0.6 percent in the BEACOPP group, and 2.5 percent
in the increased-dose BEACOPP group (P=0.03).
Solid tumors were recorded in three, eight, and two
patients, respectively, and second non-Hodgkin’s
lymphomas in seven, four, and five patients, respec-
tively.
Our results indicate that in patients with newly diag-
nosed advanced Hodgkin’s lymphoma, increased-
dose BEACOPP is superior to COPP-ABVD with re-
spect to failure-free survival (18 percentage points
better at five years) and overall survival (8 percent-
age points better). The rate of early progression was
10 percent in the COPP-ABVD group and 2 percent
in the increased-dose BEACOPP group. The differ-
ence in efficacy between increased-dose and stand-
ard BEACOPP appears to be larger than the differ-
ence between standard BEACOPP and COPP-ABVD.
In terms of overall survival, by contrast, the results
of pairwise group comparisons were not signifi-
cantly different. However, projections based on ob-
served rates of progression, relapse, toxic effects,
and second cancers suggest that increased-dose
BEACOPP confers a small, long-term survival ben-
efit.
 
19
 
 The incidence of acute toxicity increased with
increased-dose BEACOPP; grade 4 leukopenia oc-
curred in one or more cycles in 90 percent of pa-
tients. However, these events were manageable, as
indicated by the numbers of deaths, the duration of
chemotherapy, and the drug doses administered.
 
18
 
The multicenter setting of the trial, which included
local hospitals and private practices, indicates that
a regimen of increased-dose BEACOPP is generally
feasible. All prognostic groups seemed to benefit
from BEACOPP and from dose escalation.
Since the recruitment periods for the three treat-
ment groups were not identical, a shift in the char-
acteristics of the patients during the trial could have
discussion
 
* COPP-ABVD denotes cyclophosphamide, vincristine, procarbazine, predni-
sone, doxorubicin, bleomycin, vinblastine, and dacarbazine; BEACOPP bleo-
mycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, 
and prednisone; and CI confidence interval. Early progression was defined as 
progression of disease during treatment or within three months after the end 
of treatment.
† P<0.001 for the comparison with the COPP-ABVD group.
‡ P<0.001 for the comparison with the standard BEACOPP group.
§ P=0.04 for the comparison with the COPP-ABVD group.
¶P=0.002 for the comparison with the COPP-ABVD group.
 
¿ P=0.06 for the comparison with the standard BEACOPP group.
 
Table 4. Outcome of Treatment and Five-Year Survival Rates.*
Variable
COPP-
ABVD
(N=260)
Standard
BEACOPP
(N=469)
Increased-Dose
BEACOPP
(N=466)
 
percent (95% CI)
 
Complete remission 85 (80–89) 88 (85–91) 96 (93–97)
Early progression 10 (7–15) 8 (5–10) 2 (1–4)†‡
Freedom from treatment
failure at 5 yr
69 (63–75) 76 (72–80)§ 87 (83–91)†‡
Overall survival at 5 yr 83 (78–87) 88 (85–91) 91 (88–94)¶¿
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resulted in bias. We compared these characteristics
among the three groups in each recruitment year but
found no relevant differences or consistent trends
over time. We repeated all group comparisons for
the period from February 1994 through October
1996, during which patients were recruited for all
three groups, and obtained results similar to those
reported above.
Other randomized trials have demonstrated that
the efficacy of MOPP-ABVD; hybrid MOPP plus dox-
orubicin, bleomycin, and vinblastine (MOPP-ABV);
and ABVD is similar, with long-term (5 to 10 years)
progression-free survival rates of 61 to 71 per-
cent.
 
1,2
 
 Numerous variants of these regimens have
been tested,
 
3-5
 
 but none have improved treatment
efficacy. In contrast, the estimated rate of free-
 
Figure 2. Kaplan–Meier Analysis of the Probability of Freedom from Treatment Failure (Panel A) and Overall Survival 
(Panel B).
 
P values were calculated with use of the log-rank test for all three pairwise differences between groups. Numbers in pa-
rentheses are the numbers of patients. COPP-ABVD denotes cyclophosphamide, vincristine, procarbazine, prednisone, 
doxorubicin, bleomycin, vinblastine, and dacarbazine, and BEACOPP bleomycin, etoposide, doxorubicin, cyclophospha-
mide, vincristine, procarbazine, and prednisone. Tick marks indicate censored survival data.
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dom from treatment failure with increased-dose
BEACOPP is currently estimated as 89 percent at
three years and 87 percent at five years.
Three reports of interim results, however, com-
pare favorably with our results for increased-dose
BEACOPP. A five-year progression-free survival rate
of 89 percent was achieved with the Stanford V
regimen (mechlorethamine, doxorubicin, etopo-
side, vincristine, vinblastine, bleomycin, and pred-
nisone),
 
20
 
 an event-free survival rate of 82 percent
was obtained at five years by the European Organi-
zation for Research and Treatment of Cancer with
the MOPP-ABV regimen,
 
21
 
 and a progression-free
survival rate of 82 percent at five years was reported
with a hybrid regimen consisting of six courses of
chlorambucil, vinblastine, procarbazine, predni-
sone, etoposide, vincristine, and doxorubicin fol-
lowed by local irradiation.
 
22
 
That the proportion of our patients who received
radiotherapy was greater in the two BEACOPP
groups (71 percent) than in the COPP-ABVD group
(64 percent) can largely be attributed to the greater
incidence of initial bulky disease in these groups (68
percent in the BEACOPP group and 67 percent in
the increased-dose BEACOPP group, as compared
with 58 percent in the COPP-ABVD group), which
itself was presumably due to chance. Furthermore,
the shorter planned duration of BEACOPP therapy
(24 weeks, as compared with 32 weeks for COPP-
ABVD) allows less time for residual tumor to shrink.
The occurrence of nine cases of acute leukemia
after increased-dose BEACOPP seems alarming, es-
pecially as compared with the low leukemogenicity
of the ABVD regimen.
 
23,24
 
 However, this compli-
cation must be weighed against the lower rate of
early progression and higher rates of failure-free
survival and overall survival rates at five years,
 
25
 
and with the fact that secondary leukemias are like-
ly to be induced in later years as a result of treat-
ment for early progression or relapse.
 
26,27
 
 Further
study is needed before a reliable assessment of the
long-term risks of standard and increased-dose
BEACOPP can be made.
Reliable data on the long-term gonadal toxicity
of BEACOPP are not available, but it should be as-
sumed that, as is the case with COPP-ABVD and
similar regimens, a high proportion of patients,
male and female, will become infertile.
 
28
 
 This dis-
advantage is shared by MOPP-containing regimens
but not by those that include ABVD, since such reg-
imens largely preserve male fertility.
 
29
 
 The impor-
tance of this aspect must be weighed against the
avoidance of progression and relapse of advanced
disease in each patient. Infertility after therapy may
be compensated for by the use of cryopreservation
techniques before therapy.
 
30
 
Increased-dose BEACOPP therapy is more ex-
pensive than COPP-ABVD, given the direct medical
costs of inpatient stays, chemotherapy drugs, and
filgrastim. Nevertheless, the incremental cost-effec-
tiveness ratio with respect to the gain in overall sur-
vival appears to be favorable.
 
31
 
In conclusion, our results suggest that both
BEACOPP and the principle of a moderate filgras-
tim-supported escalation in the dose are promis-
ing treatment strategies for advanced Hodgkin’s
disease. Increased-dose BEACOPP is an attractive
treatment option for adults up to about 60 years of
age. The need for consolidation radiotherapy,
which was administered to 71 percent of patients
after BEACOPP, remains unproved
 
32
 
 and is being
investigated.
 
33
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* A score of 0 indicates the absence of all adverse prognostic factors, and a 
score of 7 the presence of all adverse prognostic factors. A total of 306 pa-
tients had a score of 0 to 1, 465 had a score of 2 to 3, 169 had a score of 4 to 5, 
and 255 had unknown scores. COPP-ABVD denotes cyclophosphamide, vin-
cristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, and 
dacarbazine, and BEACOPP bleomycin, etoposide, doxorubicin, cyclophos-
phamide, vincristine, procarbazine, and prednisone.
† Early progression was defined as progression of disease during treatment or 
 
within three months after the end of treatment.
 
Table 5. Rates of Early Progression and Five-Year Kaplan–Meier Estimates 
of the Rates of Freedom from Treatment Failure, According to 
the International Prognostic Index.*
International Prognostic Index
COPP-
ABVD
Standard
BEACOPP
Increased-Dose
BEACOPP
 
percent
 
Early progression†
Good (0–1)
Fair (2–3)
Poor (4–7)
10
11
18
6
9
9
2
2
3
Freedom from treatment failure at 5 yr
Good (0–1)
Fair (2–3)
Poor (4–7)
79
67
59
81
72
74
92
87
82
Overall survival at 5 yr
Good (0–1)
Fair (2–3)
Poor (4–7)
92
84
67
93
86
81
95
90
82
The New England Journal of Medicine 
Downloaded from nejm.org at MAX DELBRUECK CENTRUM FOR MOLECULAR MED on April 2, 2014. For personal use only. No other uses without permission. 
 Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
348;24
 
www.nejm.org june 
 
12
 
, 
 
2003
 
The
 
 new england journal 
 
of
 
 medicine
 
2394
 
appendix
 
The following persons were responsible for the trial: 
 
Chairman
 
 — V. Diehl (University of Cologne, Cologne, Germany); 
 
Coordinators
 
 — B.
Lathan, M. Pfreundschuh, and H. Tesch (University of Cologne, Cologne, Germany); 
 
Central monitoring
 
 — H. Nisters-Backes and T. Koch
(University of Cologne, Cologne, Germany); 
 
Data management
 
 — T. Schober (University of Cologne, Cologne, Germany); 
 
Statistical analysis
 
— J. Franklin and U. Paulus (University of Cologne, Cologne, Germany), D. Hasenclever and M. Loeffler (University of Leipzig, Leipzig,
Germany); 
 
Pathology review
 
 — A. Georgii (Hannover Medical School, Hannover, Germany) and H.-C. Mueller-Hermelink (University of
Frankfurt, Frankfurt, Germany); and 
 
Radiotherapy review
 
 — E. Duehmke (University of Munich, Munich, Germany).
The following participating institutions recruited at least three patients into the study and are listed in descending order of the numbers
recruited (clinics are in Germany unless otherwise noted): Bern, Switzerland, Swiss Group for Clinical Cancer Research (centers in Bern,
Basel, Lausanne, St. Gallen, and Ticino); Berlin, Universitäts-Klinikum Charité, Innere Medizin; Münster, Universitäts-Klinik, Onkolo-
gische Ambulanz 15 A West; Köln, Universitäts-Klinik, Klinik I für Innere Medizin, Ambulanz; Chemnitz, Klinikum Chemnitz/Krankenhaus
Küchwald, Klinik für Hämatologie Station 271; Göttingen, Georg-August-Universität, Medizinische Klinik Abteilung Hämatologie/Onkol-
ogie; Stuttgart, Robert-Bosch-Krankenhaus, Innere Medizin II Hämatologie/Onkologie; Homburg, Medizinische Universitäts-Klinik, Innere
Medizin. I; Karlsruhe, Städtisches Klinikum, Medizinische Klinik II/Hämatologie; Berlin, Universitäts-Klinikum Charité Mitte, Hämatologie/
Onkologie; Kiel, Städtisches Klinikum der Christian-Albrechts-Universität, II. Medizinische Klinik; Heidelberg, Universitäts-Klinikum,
Medizinische Klinik und Poliklinik V; Nürnberg, Klinikum, Klinik V Onkologie/Hämatologie; Magdeburg, Otto v. Guericke Universität,
Abteilung für Hämatologie; Karlsruhe, St. Vincentius Krankenhäuser, Zentrum für Innere Medizin; Regensburg, Universitäts-Klinik, Klin-
ik I für Innere Medizin; Freiburg, Medizinische Universitäts-Klinik, Innere Medizin I, Abteilung Hämatologie/Onkologie; Gießen, Justus-
Liebig-Universität, Innere Medizin Hämatologie/Onkologie; Heidelberg, Thorax-Klinik der LVA Baden, Internistisch-Onkologische Abtei-
lung; Prague, Czech Republic, Fakultni Nemocnice, Oddelení klinické hematologia; Braunschweig, Städtisches Klinikum, Medizinische
Klinik; Marburg, Klinikum der Philipps-Universität, Innere Medizin Hämatologie/Onkologie; Essen, Universitäts-Klinik, Hämatologische
Tagesklinik; Hannover, Dr. Wysk, Hämatologische/Onkologische Gemeinschaftspraxis; Hamburg, Universität Krankenhaus Eppendorf,
Abteilung Hämatologie/Onkologie; Würzburg, Universitäts-Klinik und Poliklinik, Onkologische Abteilung; Minden, Klinikum, Abteilung
Hämatologie/Onkologie; Erlangen, Universitäts-Klinik, Medizinische Klinik und Poliklinik III; Lübeck, Städtisches Krankenhaus Süd,
Abteilung Hämatologie/Onkologie; Lübeck, Medizinische Universität, Innere Medizin Hämatologie/Onkologie; Dresden, Universitäts-
Klinik C.G. Carus, Medizinische Klinik I; München, Klinikum “Rechts der Isar,” Medizinische Klinik III; Saarbrücken, Caritasklinik St.
Theresia, Klinik für Onkologie und Immunologie; Krefeld, Städtische Krankenanstalten, Medizinische Klinik II; Offenburg, Klinikum,
Medizinische Klinik II; Tübingen, Eberhard-Karls-Universität, Abteilung Innere Medizin II Hämatologische Ambulanz; Jena, Friedrich-
Schiller-Universität, Klinik für Innere Medizin; Bayreuth, Klinikum, Medizinische Klinik I; Stuttgart, Bürgerhospital, Medizinische Klinik
I; Essen, Evangelisches Krankenhaus, Innere Medizin; Heilbronn, Städtisches Krankenhaus, I. Medizinische Klinik; Hamm, Ev. Kranken-
haus, Innere Medizin/Hämatologie/Onkologie; Darmstadt, Städtische Kliniken, Medizinische Klinik V/Hämatologie; Dortmund, St. Johannes
Hospital, Medizinische Klinik; München, Akademisches Lehrkrankenhaus, I. Medizinische Abteilung; Eschweiler, St. Antonius Hospital,
Abteilung für Hämatologie/Onkologie; Berlin, Klinikum Neukölln, Abteilung Hämatologie/Onkologie; Frankfurt/Oder, Klinikum, Klinik
für Innere Medizin; Frankfurt, Krankenhaus Nordwest, II. Medizinische Klinik; Lahr, Klinikum Lahr, Medizinische Klinik/Gastroenterolo-
gie; Sindelfingen, Städtisches Krankenhaus, Innere Medizin; Regensburg, Krankenhaus der Barmherzigen Brüder, Klinik für internis-
tische Onkologie und Hämatologie; Wiesbaden, Dr. Horst-Schmidt-Kliniken, Innere Medizin III, Hämatologie/Onkologie; Stade, Klinik
Dr. Hancken, Abteilung für Hämatologie; Trier, Krankenanstalt Mutterhaus der Borromäerinnen, Medizinische Klinik; Hildesheim, St.
Bernward-Krankenhaus, Medizinische Klinik II; Halle, Martin-Luther-Universität Halle-Wittgenstein, Medizinische Klinik und Poliklinik
IV; Kassel, Klinikum, Hämatologie/Onkologie; Rostock, Universität, Innere Medizin Onkologie/Hämatologie; Ravensburg, Oberschwaben-
klinik, Innere Abteilung; Duisburg, St. Johannes Hospital, Medizinische Klinik II; Hagen, Marienhospital, Hämatologische/Onkologische
Station; Mönchengladbach, Kliniken Maria Hilf, Abteilung I; Jena, Dr. med. Hahnfeld, Hämatologische/Onkologische Gemeinschaftsprax-
is; Aurich, Kreis-Krankenhaus, Innere Medizin/Hämatologie; Hannover, Medizinische Hochschule, Abteilung Hämatologie/Onkologie;
Hamburg, Gemeinschaftspraxis Prof. Dr. Kleeberg; Trier, Krankenhaus der Barmherzigen Brüder, I. Medizinische Abteilung; Bonn, Uni-
versitäts-Klinik, Medizinische Klinik und Poliklinik; Köln, Krankenhaus Merheim, Lungenklinik Onkologische Abteilung; Ludwigshafen,
Klinikum der Stadt, Medizinische Klinik A; Duisburg, Johanniter-Krankenhaus Rheinhausen, Medizinische Klinik II/Onkologie; Stuttgart,
Diakonissen-Krankenhaus, Innere Medizin II; Günzburg, Kreis-Krankenhaus, Innere Medizin; Pforzheim, Städtisches Krankenhaus,
Medizinische Klinik II; Berlin, Vivantes, Hämatologie-Onkologische Beratung; Ulm, Universitäts-Klinik, Innere Abteilung III; München,
Städtisches Krankenhaus Harlaching, IV. Medizinische Abteilung; Kaiserslautern, Westpfalz Klinikum, Innere med. I/Hämatologie;
Lüdenscheid, Kreis-Krankenhaus, Innere Abteilung/Onkologie; Oldenburg, Dr. Otremba, Gemeinschaftspraxis Innere Medizin; Dresden,
Krankenhaus Dresden-Friedrichstadt, I. Medizinische Klinik; Hamburg, Dr. Verpoort, Praxis Innere Medizin; Münster, Dr. Kriebel-
Schmitt, Hämatologische/Onkologische Gemeinschaftspraxis; Gütersloh, Städtisches Krankenhaus, Medizinische Klinik/Hämatologie;
Oldenburg, Städtische Kliniken, Innere Medizin II; Stuttgart, Katharinenhospital, Klinik für Onkologie; Waldbröl, Kreis-Krankenhaus,
Medizinische Klinik; Limburg, St. Vincentius Krankenhaus, Abteilung Hämatologie; Freiburg, Evangelisches Diakonie-Krankenhaus, Innere
Abteilung; Aalen, Kreis-Krankenhaus Ostalb-Klinikum, Innere Abteilung; Lebach, Caritas-Krankenhaus, Innere Medizin; Hameln, Kran-
kenhaus des Kreises Hameln/Pyrmont, Innere Abteilung; Bonn, Medizinische Poliklinik, Innere Medizin; München, Klinikum Großhad-
ern, Klinik III für Hämatologie/Onkologie; Neuss, Lukas-Krankenhaus, Medizinische Klinik II; Magdeburg, Städtisches Klinikum, Innere
Medizin Abteilung Hämatologie/Onkologie; Leipzig, Universitäts-Klinik, Medizinische Abteilung Hämatologie/Onkologie; Hannover,
Krankenhaus Siloah, Klinik für Hämatologie und Onkologie; Hamburg, Allg. Krankenhaus Barmbeck, Onkologische Abteilung; Freiburg,
Klinik für Tumorbiologie, Klinik für Internistische Onkologie; Trier, Dr. Grundheber, Onkologische Schwerpunktpraxis; Greifswald,
Ernst-Moritz-Arndt-Universität, Innere Medizin C Abteilung Hämatologie/Onkologie; Mülheim/Ruhr, Ev. Krankenhaus, Medizinische  Klin-
ik; Innsbruck, Austria, Universitäts-Klinikum, Institut für Epidemiologie; Worms, Dr. Burkhard, Onkologische Schwerpunktpraxis; Wup-
pertal, Bethesda Krankenhaus, Innere Abteilung; Herford, Klinikum Kreis, Medizinische Klinik II.
The New England Journal of Medicine 
Downloaded from nejm.org at MAX DELBRUECK CENTRUM FOR MOLECULAR MED on April 2, 2014. For personal use only. No other uses without permission. 
 Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
348;24
 
www.nejm.org june 
 
12, 2003
 
beacopp for advanced hodgkin’s disease
 
2395
 
references
 
1.
 
Connors JM, Klimo P, Adams G, et al.
Treatment of advanced Hodgkin’s disease
with chemotherapy — comparison of MOPP/
ABV hybrid regimen with alternating courses
of MOPP and ABVD: a report from the Na-
tional Cancer Institute of Canada clinical
trials group. J Clin Oncol 1997;15:1638-45.
[Erratum, J Clin Oncol 1997;15:2762.]
 
2.
 
Canellos GP, Anderson JR, Propert KJ,
et al. Chemotherapy of advanced Hodgkin’s
disease with MOPP, ABVD, or MOPP alter-
nating with ABVD. N Engl J Med 1992;327:
1478-84.
 
3.
 
Cullen MH, Stuart NSA, Woodroffe C, et
al. ChlVPP/PAB1OE and radiotherapy in ad-
vanced stage Hodgkin’s disease. J Clin Oncol
1994;12:779-87.
 
4.
 
Hancock BW, Vaughan Hudson G,
Vaughan Hudson B, et al. LOPP alternating
with EVAP is superior to LOPP alone in the
initial treatment of advanced Hodgkin’s dis-
ease: results of a British National Lympho-
ma Investigation trial. J Clin Oncol 1992;10:
1252-8.
 
5.
 
Longo DL, Duffey PL, DeVita VT Jr, et al.
Treatment of advanced-stage Hodgkin’s dis-
ease: alternating noncrossresistant MOPP/
CABS is not superior to MOPP. J Clin Oncol
1991;9:1409-20.
 
6.
 
Josting A, Franklin J, May M, et al. New
prognostic score based on treatment out-
come of patients with relapsed Hodgkin’s
lymphoma registered in the database of the
German Hodgkin’s Lymphoma Study
Group. J Clin Oncol 2002;20:221-30.
 
7.
 
Bonfante V, Santoro A, Viviani S, et al.
Outcome of patients with Hodgkin’s dis-
ease failing after primary MOPP-ABVD.
J Clin Oncol 1997;15:528-34.
 
8.
 
Frei E III, Canellos GP. Dose: a critical
factor in cancer chemotherapy. Am J Med
1980;69:585-94.
 
9.
 
van Rijswijk REN, Haanen C, Dekker
AW, de Meijer AJ, Verbeek J. Dose intensity
of MOPP chemotherapy and survival in
Hodgkin’s disease. J Clin Oncol 1989;7:
1776-82.
 
10.
 
Hasenclever D, Loeffler M, Diehl V. Ra-
tionale for dose escalation of first line con-
ventional chemotherapy in advanced Hodg-
kin’s disease. Ann Oncol 1996;7:Suppl 4:
95-8.
 
11.
 
Loeffler M, Hasenclever D, Diehl V.
Model based development of the BEACOPP
regimen for advanced stage Hodgkin’s dis-
ease. Ann Oncol 1998;9:Suppl 5:S73-S78.
 
12.
 
Diehl V, Sieber M, Rüffer U, et al.
BEACOPP: an intensified chemotherapy reg-
imen in advanced Hodgkin’s disease. Ann
Oncol 1997;8:143-8.
 
13.
 
Tesch H, Diehl V, Lathan B, et al. Moder-
ate dose escalation for advanced stage Hodg-
kin’s disease using the bleomycin, etoposide,
adriamycin, cyclophosphamide, vincristine,
procarbazine and prednisone scheme and
adjuvant radiotherapy: a study of the German
Hodgkin’s Lymphoma Study Group. Blood
1998;92:4560-7.
 
14.
 
Diehl V, Franklin J, Hasenclever D, et al.
BEACOPP, a new dose-escalated and accel-
erated regimen, is at least as effective as
COPP/ABVD in patients with advanced-stage
Hodgkin’s lymphoma: interim report from
a trial of the German Hodgkin’s Lymphoma
Study Group. J Clin Oncol 1998;16:3810-21.
 
15.
 
Diehl V, Franklin J, Paulus U, et al.
BEACOPP chemotherapy improves survival,
and dose escalation further improves tumour
control in advanced stage Hodgkin’s disease:
GHSG HD9 results. Leuk Lymphoma 2001;
42:Suppl 2:16-7. abstract.
 
16.
 
Whitehead J. The design and analysis of
sequential clinical trials. 2nd ed. Chichester,
England: John Wiley, 1992.
 
17.
 
Hasenclever D, Diehl V. A prognostic
score for advanced Hodgkin’s disease.
N Engl J Med 1998;339:1506-14.
 
18.
 
Engel C, Loeffler M, Schmitz S, Tesch H,
Diehl V. Acute hematologic toxicity and
practicability of dose-intensified BEACOPP
chemotherapy for advanced stage Hodg-
kin’s disease. Ann Oncol 2000;11:1105-14.
 
19.
 
Carde P, Cavalli F, Diehl V, Franklin J. Is
escalated BEACOPP a standard therapy for
advanced Hodgkin’s disease? Hematol J
2000;1:282-90.
 
20.
 
Horning SJ, Hoppe RT, Breslin S, Bar-
tlett NL, Brown BW, Rosenberg SA. Stan-
ford V and radiotherapy for locally extensive
and advanced Hodgkin’s disease: mature re-
sults of a prospective clinical trial. J Clin On-
col 2002;20:630-7.
 
21.
 
Raemaekers J, Burgers M, Henry-Amar
H, et al. Patients with stage III/IV Hodgkin’s
disease in partial remission after MOPP/
ABV chemotherapy have excellent progno-
sis after additional involved-field radiother-
apy: interim results from the ongoing
EORTC-LCG and GPMC phase III trial. Ann
Oncol 1997;8:Suppl 1:111-4.
 
22.
 
Radford JA, Rohatiner AZS, Ryder WDJ,
et al. ChlVPP/EVA hybrid versus the weekly
VAPEC-B regimen for previously untreated
Hodgkin’s disease. J Clin Oncol 2002;20:
2988-94.
 
23.
 
Valagussa P, Santoro A, Fossati-Bellani
F, Banfi A, Bonadonna G. Second acute leu-
kemia and other malignancies following
treatment for Hodgkin’s disease. J Clin On-
col 1986;4:830-7.
 
24.
 
Duggan D, Petroni G, Johnson J, et al.
MOPP/ABV versus ABVD for advanced
Hodgkin’s disease — a preliminary report
of CALGB 8952 (with SWOG, ECOG, NCIC).
Prog Proc Am Soc Clin Oncol 1997;16:12a.
abstract.
 
25.
 
Hess CF, Kortmann RD, Schmidberger
H, Bamberg M. How relevant is secondary
leukaemia for initial treatment selection in
Hodgkin’s disease? Eur J Cancer 1994;30A:
1441-7.
 
26.
 
van Leeuwen FE, Chorus AMJ, van den
Belt-Dusebout AW, et al. Leukemia risk fol-
lowing Hodgkin’s disease: relation to cumu-
lative dose of alkylating agents, treatment
with teniposide combinations, number of
episodes of chemotherapy, and bone mar-
row damage. J Clin Oncol 1994;12:1063-73.
 
27.
 
Micallef INM, Lillington DM, Apostoli-
dis J, et al. Therapy-related myelodysplasia
and secondary acute myelogenous leukemia
after high-dose therapy with autologous
hematopoietic progenitor-cell support for
lymphoid malignancies. J Clin Oncol 2000;
18:947-55.
 
28.
 
Kreuser ED, Felsenberg D, Behles C, et
al. Long-term gonadal dysfunction and its
impact on bone mineralization in patients
following COPP/ABVD chemotherapy for
Hodgkin’s disease. Ann Oncol 1992;3:
Suppl 4:105-10.
 
29.
 
Brusamolino E, Lunghi F, Orlandi E, et
al. Treatment of early-stage Hodgkin’s dis-
ease with four cycles of ABVD followed by
adjuvant radio-therapy: analysis of efficacy
and long-term toxicity. Haematologica 2000;
85:1032-9.
 
30.
 
Khalifa E, Oehninger S, Acosta AA, et al.
Successful fertilization and pregnancy out-
come in in-vitro fertilization using cryopre-
served/thawed spermatozoa from patients
with malignant diseases. Hum Reprod 1992;
7:105-8.
 
31.
 
Walshe R, Glossmann J-P, Waldschmidt
D, et al. Comparing costs and effectiveness
of COPP/ABVD and BEACOPP escalated reg-
imens for advanced stages of Hodgkin’s dis-
ease. Leuk Lymphoma 2001;42:Suppl 2:
106. abstract.
 
32.
 
Loeffler M, Brosteanu O, Hasenclever D,
et al. Meta-analysis of chemotherapy versus
combined modality treatment trials in Hodg-
kin’s disease. J Clin Oncol 1998;16:818-29.
 
33.
 
Franklin J, Diehl V. Current clinical trials
for the treatment of advanced-stage Hodg-
kin’s disease: BEACOPP. Ann Oncol 2002;
13:Suppl 1:98-101.
 
Copyright © 2003 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org at MAX DELBRUECK CENTRUM FOR MOLECULAR MED on April 2, 2014. For personal use only. No other uses without permission. 
 Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
